| Literature DB >> 30394934 |
Yasemin Sanli1, Katherine Zukotynski2, Erik Mittra3, Delphine L Chen4, Helen Nadel5, Ryan D Niederkohr6, Rathan M Subramaniam.
Abstract
There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30394934 DOI： 10.1097/RLU.0000000000002247
Source DB: PubMed Journal: Clin Nucl Med ISSN： 0363-9762 Impact factor: 7.794